China's leading cardiovascular implant device and transcatheter tricuspid valve repair system technology company, SHHH Medical Technology Co., Ltd. has recently completed a round of financing of nearly 100 million yuan. The funds raised will be used to continue to advance the continuous research and development of tricuspid valve intervention products, clinical approval, and the development of other structural heart disease-related product pipelines.
SHHH is a high-tech company engaged in the R&D and production of structural heart disease interventional medical devices. It has China's first self-developed transvascular tricuspid valve interventional repair system. In addition, SHHH stated that “while completing the tricuspid valve transvascular repair products, the company has also developed interventional products for mitral regurgitation.”
The company's core product, the transcatheter tricuspid valve repair system, was developed for the disease of tricuspid regurgitation. Tricuspid regurgitation is mostly secondary to left heart (mitral or aortic valve) disease. It is a common structural heart disease. If the patient does not receive treatment in time, it will turn into heart failure. Once heart failure occurs, the patient will be within 5 years The mortality rate will exceed 50%. Therefore, how to ensure the smooth and safe treatment of tricuspid regurgitation and reduce the progressive development of severe tricuspid regurgitation with a mortality rate of up to 30% after the second thoracotomy has become a major issue.
At present, tricuspid valve regurgitation mainly relies on surgical thoracotomy, but this treatment method has problems such as difficulty in carrying out, high risk of surgery, and great harm to patients. Therefore, the interventional repair of tricuspid valve regurgitation has been recommended by the global guideline consensus. Companies on the structural heart disease track are developing and acquiring tricuspid valve interventional repair products. The transcatheter tricuspid valve repair system developed by SHHH is currently the fastest-growing product in China, and no competing products have entered the clinical stage.
SHHH said: “The Kay's procedure used in the transcatheter tricuspid valve repair system has decades of experience in cardiac surgery and evidence-based evidence. It can completely restore the surgical procedure while reducing the risk of patients. A lot of new attempts have been made in part and the entire procedure."